ORIC ORIC Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 13:12
Why ORIC matters now
ORIC Pharmaceuticals, Inc. (ORIC) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.64 with -2.74% on the session and $1.10B in market capitalization; recent performance reads 1-month +6.52% and YTD +3.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-35.8M, and EPS of $-0.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.7%.
The latest indexable market news headline is "ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.50; recent insider activity includes Piscitelli Dominic filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.15
P/S
0.00
EV/EBITDA
-6.16
DCF Value
$0.35
FCF Yield
-12.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.3%
ROA
-31.0%
ROIC
-35.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-35.8M | $-0.34 |
| Q4 2025 | $0.00 | $-30.5M | $-0.30 |
| FY 2025 | $0.00 | $-129.5M | $-1.47 |
| Q3 2025 | $0.00 | $-32.6M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.25
Target (Median)
$18.50
Target Range
$15.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.06
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.